Annual EBIT
-$498.09 M
+$138.63 M+21.77%
31 December 2023
Summary:
Sarepta Therapeutics annual earnings before interest & taxes is currently -$498.09 million, with the most recent change of +$138.63 million (+21.77%) on 31 December 2023. During the last 3 years, it has fallen by -$4.97 million (-1.01%). SRPT annual EBIT is now -22540.36% below its all-time high of -$1.70 million.SRPT EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
$38.92 M
+$20.52 M+111.44%
30 September 2024
Summary:
Sarepta Therapeutics quarterly earnings before interest & taxes is currently $38.92 million, with the most recent change of +$20.52 million (+111.44%) on 30 September 2024. Over the past year, it has increased by +$66.87 million (+239.29%). SRPT quarterly EBIT is now -54.92% below its all-time high of $86.35 million, reached on 31 March 2017.SRPT Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
$148.55 M
+$66.87 M+81.86%
30 September 2024
Summary:
Sarepta Therapeutics TTM earnings before interest & taxes is currently $148.55 million, with the most recent change of +$66.87 million (+81.86%) on 30 September 2024. Over the past year, it has increased by +$786.86 million (+123.27%). SRPT TTM EBIT is now at all-time high.SRPT TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SRPT EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +21.8% | +239.3% | +123.3% |
| 3 y3 years | -1.0% | +222.0% | +135.4% |
| 5 y5 years | -51.4% | +132.8% | +125.1% |
SRPT EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -40.1% | +21.8% | -14.7% | +107.7% | at high | +114.1% |
| 5 y | 5 years | -51.4% | +27.1% | -14.7% | +107.7% | at high | +114.1% |
| alltime | all time | <-9999.0% | +27.1% | -54.9% | +107.7% | at high | +114.1% |
Sarepta Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $38.92 M(+111.4%) | $148.55 M(+81.9%) |
| June 2024 | - | $18.41 M(-59.6%) | $81.68 M(+51.5%) |
| Mar 2024 | - | $45.61 M(+0.0%) | $53.91 M(-110.8%) |
| Dec 2023 | -$498.09 M(-21.8%) | $45.60 M(-263.2%) | -$498.09 M(-22.0%) |
| Sept 2023 | - | -$27.95 M(+198.5%) | -$638.31 M(-25.1%) |
| June 2023 | - | -$9.36 M(-98.2%) | -$852.05 M(-19.2%) |
| Mar 2023 | - | -$506.39 M(+435.2%) | -$1.05 B(+65.7%) |
| Dec 2022 | -$636.72 M(+79.1%) | -$94.62 M(-60.9%) | -$636.72 M(-1.7%) |
| Sept 2022 | - | -$241.68 M(+14.0%) | -$647.94 M(+47.9%) |
| June 2022 | - | -$212.06 M(+140.0%) | -$438.17 M(+50.0%) |
| Mar 2022 | - | -$88.35 M(-16.5%) | -$292.03 M(-17.8%) |
| Dec 2021 | -$355.42 M(-27.9%) | -$105.84 M(+231.7%) | -$355.42 M(-15.2%) |
| Sept 2021 | - | -$31.91 M(-51.6%) | -$419.34 M(-26.4%) |
| June 2021 | - | -$65.93 M(-56.6%) | -$569.94 M(-11.1%) |
| Mar 2021 | - | -$151.74 M(-10.6%) | -$641.10 M(+30.0%) |
| Dec 2020 | -$493.12 M(-27.8%) | -$169.75 M(-7.0%) | -$493.12 M(-10.3%) |
| Sept 2020 | - | -$182.51 M(+33.1%) | -$549.97 M(+13.2%) |
| June 2020 | - | -$137.09 M(+3544.0%) | -$486.03 M(-21.3%) |
| Mar 2020 | - | -$3.76 M(-98.3%) | -$617.75 M(-9.6%) |
| Dec 2019 | -$683.21 M(+107.7%) | -$226.60 M(+91.1%) | -$683.21 M(+15.6%) |
| Sept 2019 | - | -$118.58 M(-55.9%) | -$591.03 M(+9.7%) |
| June 2019 | - | -$268.80 M(+288.3%) | -$538.84 M(+45.4%) |
| Mar 2019 | - | -$69.22 M(-48.5%) | -$370.54 M(+12.7%) |
| Dec 2018 | -$328.90 M(+668.0%) | -$134.43 M(+102.5%) | -$328.90 M(+52.4%) |
| Sept 2018 | - | -$66.39 M(-33.9%) | -$215.84 M(+11.0%) |
| June 2018 | - | -$100.50 M(+264.3%) | -$194.38 M(+24.0%) |
| Mar 2018 | - | -$27.59 M(+29.1%) | -$156.76 M(+266.0%) |
| Dec 2017 | -$42.83 M(-83.9%) | -$21.36 M(-52.4%) | -$42.83 M(-60.8%) |
| Sept 2017 | - | -$44.92 M(-28.6%) | -$109.14 M(-9.6%) |
| June 2017 | - | -$62.89 M(-172.8%) | -$120.75 M(+0.8%) |
| Mar 2017 | - | $86.35 M(-198.5%) | -$119.85 M(-54.9%) |
| Dec 2016 | -$265.37 M(+21.4%) | -$87.68 M(+55.1%) | -$265.90 M(+10.3%) |
| Sept 2016 | - | -$56.53 M(-8.8%) | -$241.15 M(+2.0%) |
| June 2016 | - | -$61.98 M(+3.8%) | -$236.38 M(+9.2%) |
| Mar 2016 | - | -$59.70 M(-5.1%) | -$216.50 M(-1.0%) |
| Dec 2015 | -$218.66 M(+63.4%) | -$62.93 M(+21.6%) | -$218.66 M(+9.1%) |
| Sept 2015 | - | -$51.76 M(+22.9%) | -$200.45 M(+9.9%) |
| June 2015 | - | -$42.11 M(-31.9%) | -$182.37 M(+6.9%) |
| Mar 2015 | - | -$61.86 M(+38.3%) | -$170.53 M(+27.5%) |
| Dec 2014 | -$133.79 M(+48.2%) | -$44.72 M(+32.8%) | -$133.79 M(+9.7%) |
| Sept 2014 | - | -$33.67 M(+11.2%) | -$121.92 M(+7.7%) |
| June 2014 | - | -$30.27 M(+20.5%) | -$113.17 M(+13.2%) |
| Mar 2014 | - | -$25.12 M(-23.5%) | -$99.99 M(+10.8%) |
| Dec 2013 | -$90.28 M(+204.0%) | -$32.85 M(+31.7%) | -$90.28 M(+33.2%) |
| Sept 2013 | - | -$24.93 M(+45.9%) | -$67.80 M(+36.2%) |
| June 2013 | - | -$17.09 M(+10.8%) | -$49.77 M(+30.1%) |
| Mar 2013 | - | -$15.41 M(+48.7%) | -$38.24 M(+28.8%) |
| Dec 2012 | -$29.70 M(-17.3%) | -$10.37 M(+50.1%) | -$29.70 M(+4.8%) |
| Sept 2012 | - | -$6.91 M(+24.3%) | -$28.34 M(-13.4%) |
| June 2012 | - | -$5.56 M(-19.2%) | -$32.70 M(-12.3%) |
| Mar 2012 | - | -$6.87 M(-23.6%) | -$37.27 M(+3.7%) |
| Dec 2011 | -$35.93 M(+71.6%) | -$9.00 M(-20.1%) | -$35.93 M(+25.3%) |
| Sept 2011 | - | -$11.27 M(+11.3%) | -$28.67 M(+35.3%) |
| June 2011 | - | -$10.13 M(+83.1%) | -$21.19 M(+13.1%) |
| Mar 2011 | - | -$5.53 M(+217.9%) | -$18.73 M(-10.5%) |
| Dec 2010 | -$20.93 M | -$1.74 M(-54.2%) | -$20.94 M(-9.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2010 | - | -$3.80 M(-50.5%) | -$23.16 M(+3.9%) |
| June 2010 | - | -$7.67 M(-0.9%) | -$22.28 M(+13.2%) |
| Mar 2010 | - | -$7.74 M(+95.4%) | -$19.68 M(+26.9%) |
| Dec 2009 | -$15.51 M(-11.6%) | -$3.96 M(+35.6%) | -$15.51 M(+7.4%) |
| Sept 2009 | - | -$2.92 M(-42.3%) | -$14.44 M(-17.3%) |
| June 2009 | - | -$5.07 M(+42.1%) | -$17.46 M(+1.1%) |
| Mar 2009 | - | -$3.56 M(+23.2%) | -$17.28 M(-1.5%) |
| Dec 2008 | -$17.54 M(-47.0%) | -$2.89 M(-51.3%) | -$17.54 M(-13.7%) |
| Sept 2008 | - | -$5.94 M(+21.7%) | -$20.32 M(-11.3%) |
| June 2008 | - | -$4.88 M(+27.4%) | -$22.89 M(-14.8%) |
| Mar 2008 | - | -$3.83 M(-32.4%) | -$26.85 M(-18.9%) |
| Dec 2007 | -$33.11 M(+0.4%) | -$5.67 M(-33.4%) | -$33.11 M(-8.6%) |
| Sept 2007 | - | -$8.51 M(-3.7%) | -$36.21 M(+3.5%) |
| June 2007 | - | -$8.84 M(-12.3%) | -$34.97 M(+4.2%) |
| Mar 2007 | - | -$10.09 M(+15.0%) | -$33.55 M(+1.7%) |
| Dec 2006 | -$32.98 M(+88.3%) | -$8.77 M(+20.6%) | -$32.98 M(+13.3%) |
| Sept 2006 | - | -$7.27 M(-2.0%) | -$29.12 M(+22.5%) |
| June 2006 | - | -$7.42 M(-22.1%) | -$23.76 M(+10.6%) |
| Mar 2006 | - | -$9.52 M(+94.1%) | -$21.49 M(+22.7%) |
| Dec 2005 | -$17.52 M(-30.1%) | -$4.91 M(+155.8%) | -$17.52 M(-0.2%) |
| Sept 2005 | - | -$1.92 M(-62.8%) | -$17.55 M(-15.4%) |
| June 2005 | - | -$5.15 M(-7.2%) | -$20.75 M(-9.1%) |
| Mar 2005 | - | -$5.55 M(+12.3%) | -$22.84 M(-8.8%) |
| Dec 2004 | -$25.04 M(+32.7%) | -$4.94 M(-3.6%) | -$25.04 M(-8.1%) |
| Sept 2004 | - | -$5.12 M(-29.2%) | -$27.27 M(+1.7%) |
| June 2004 | - | -$7.23 M(-6.7%) | -$26.82 M(+15.9%) |
| Mar 2004 | - | -$7.75 M(+8.3%) | -$23.14 M(+22.6%) |
| Dec 2003 | -$18.87 M(-25.5%) | -$7.16 M(+53.0%) | -$18.87 M(+18.9%) |
| Sept 2003 | - | -$4.68 M(+31.7%) | -$15.87 M(-4.2%) |
| June 2003 | - | -$3.55 M(+2.1%) | -$16.56 M(-20.9%) |
| Mar 2003 | - | -$3.48 M(-16.1%) | -$20.93 M(-17.4%) |
| Dec 2002 | -$25.34 M(+64.5%) | -$4.15 M(-22.7%) | -$25.34 M(-2.2%) |
| Sept 2002 | - | -$5.37 M(-32.2%) | -$25.92 M(+8.5%) |
| June 2002 | - | -$7.92 M(+0.3%) | -$23.89 M(+20.9%) |
| Mar 2002 | - | -$7.90 M(+66.9%) | -$19.76 M(+28.3%) |
| Dec 2001 | -$15.40 M(+50.4%) | -$4.73 M(+41.5%) | -$15.40 M(+9.1%) |
| Sept 2001 | - | -$3.35 M(-11.6%) | -$14.12 M(+5.6%) |
| June 2001 | - | -$3.78 M(+6.9%) | -$13.37 M(+6.6%) |
| Mar 2001 | - | -$3.54 M(+2.5%) | -$12.54 M(+22.5%) |
| Dec 2000 | -$10.24 M(+23.4%) | -$3.45 M(+33.3%) | -$10.24 M(+12.7%) |
| Sept 2000 | - | -$2.59 M(-12.3%) | -$9.09 M(+4.5%) |
| June 2000 | - | -$2.96 M(+138.2%) | -$8.70 M(+13.8%) |
| Mar 2000 | - | -$1.24 M(-46.1%) | -$7.64 M(-4.5%) |
| Dec 1999 | -$8.30 M(+6.4%) | -$2.30 M(+4.5%) | -$8.00 M(-3.6%) |
| Sept 1999 | - | -$2.20 M(+15.8%) | -$8.30 M(+5.1%) |
| June 1999 | - | -$1.90 M(+18.8%) | -$7.90 M(+2.6%) |
| Mar 1999 | - | -$1.60 M(-38.5%) | -$7.70 M(+1.3%) |
| Dec 1998 | -$7.80 M(+100.0%) | -$2.60 M(+44.4%) | -$7.60 M(+26.7%) |
| Sept 1998 | - | -$1.80 M(+5.9%) | -$6.00 M(+17.6%) |
| June 1998 | - | -$1.70 M(+13.3%) | -$5.10 M(+10.9%) |
| Mar 1998 | - | -$1.50 M(+50.0%) | -$4.60 M(+24.3%) |
| Dec 1997 | -$3.90 M(+77.3%) | -$1.00 M(+11.1%) | -$3.70 M(+37.0%) |
| Sept 1997 | - | -$900.00 K(-25.0%) | -$2.70 M(+50.0%) |
| June 1997 | - | -$1.20 M(+100.0%) | -$1.80 M(+200.0%) |
| Mar 1997 | - | -$600.00 K | -$600.00 K |
| Dec 1996 | -$2.20 M | - | - |
FAQ
- What is Sarepta Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Sarepta Therapeutics?
- What is Sarepta Therapeutics annual EBIT year-on-year change?
- What is Sarepta Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly EBIT year-on-year change?
- What is Sarepta Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Sarepta Therapeutics?
- What is Sarepta Therapeutics TTM EBIT year-on-year change?
What is Sarepta Therapeutics annual earnings before interest & taxes?
The current annual EBIT of SRPT is -$498.09 M
What is the all time high annual EBIT for Sarepta Therapeutics?
Sarepta Therapeutics all-time high annual earnings before interest & taxes is -$1.70 M
What is Sarepta Therapeutics annual EBIT year-on-year change?
Over the past year, SRPT annual earnings before interest & taxes has changed by +$138.63 M (+21.77%)
What is Sarepta Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of SRPT is $38.92 M
What is the all time high quarterly EBIT for Sarepta Therapeutics?
Sarepta Therapeutics all-time high quarterly earnings before interest & taxes is $86.35 M
What is Sarepta Therapeutics quarterly EBIT year-on-year change?
Over the past year, SRPT quarterly earnings before interest & taxes has changed by +$66.87 M (+239.29%)
What is Sarepta Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of SRPT is $148.55 M
What is the all time high TTM EBIT for Sarepta Therapeutics?
Sarepta Therapeutics all-time high TTM earnings before interest & taxes is $148.55 M
What is Sarepta Therapeutics TTM EBIT year-on-year change?
Over the past year, SRPT TTM earnings before interest & taxes has changed by +$786.86 M (+123.27%)